Bharat Biotech expands its manufacturing capacity to produce 70 crore doses of Covaxin annually

Jammu, April 21: Bharat Biotech has expanded its manufacturing capacity across multiple facilities in Hyderabad and Bangalore to produce 700 million doses of Covaxin annually. The government on Monday approved a payment of about 4,500 crore rupees as advance to vaccine makers including Bharat Biotech and Serum Institute of India (SII) that is producing AstraZeneca’s Covishield in India. The move came ahead of opening the vaccination drive to all citizens over 18 years of age. SII will supply 200 million doses and Bharat Biotech is set to supply another 90 million doses to the government by July at a pre-agreed rate of 150 rupees per dose.